Biomarker in ME/CFS {#Sec1}
===================

Although the exact pathogenesis of myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is still unknown, the most plausible hypothesis is that it is a complex multifactorial syndrome in which immunological and environmental factors play a crucial role. In addition, the severe fatigue, post-exertional malaise, cognitive impairment, and autonomic dysfunction that delineate the disease point to the involvement of both the nervous system as well as metabolic disturbances \[[@CR1]\]. Infection by various pathogens, including herpes viruses and enteroviruses, but also intracellular bacteria, are known as triggers of disease. The complex clinical picture and the disagreement on potential pathomechanisms make ME/CFS a controversial entity and compel the research for disease biomarkers that could aid in the diagnostic and clinical management. Biomarker per definition may include both markers with a certain sensitivity and specificity for diagnosing ME/CFS as well as those which may allow to classify subtypes of the disease, be of value as indicators of prognosis, and to be predictive for response to treatment \[[@CR2]\].

The EUROMENE ME/CFS Biomarker Landscape project {#Sec2}
===============================================

EUROMENE is a network of researchers and clinicians from 17 European countries and one COST (Cooperation in Science and Technology) near neighbor country on ME/CFS supported by the European COST program within Horizon 2020 (<http://www.cost.eu/COST_Actions/ca/CA15111>).

The aims of EUROMENE are to foster strategies for collaboration and harmonization of diagnosis and research, and to compile an inventory of clinical and scientific data in ME/CFS. The Biomarker working group will also try to develop guidelines for the usage of biomarkers and synchronization of biomarker research.

As a first step, a database for active biomarker research in Europe was established called the EUROMENE ME/CFS Biomarker Landscape project. To achieve this, EUROMENE members performed a search for publications on biomarkers within their countries. The search strategy used the medical subject headings (MeSH) term "chronic fatigue syndrome", which includes myalgic encephalomyelitis, and the respective country, and selected all publications from the last 5 years (2012--2016). The searches were reviewed by members of the biomarker working group. Studies not involving patients with ME/CFS, non-biomarker, and sole treatment studies were excluded, only one review article was included.

A total number of 39 studies were identified. Studies were categorized as being immunological, infection-related, metabolic or neurological. We summarize the findings in Fig. [1](#Fig1){ref-type="fig"}, which shows the number and type of studies identified in each country, represented by pie charts---their sizes being proportional to the number of identified studies, and their pieces representing the distinct categories of the studies. The number of research groups working on ME/CFS biomarkers in the EU countries is also illustrated in Fig. [1](#Fig1){ref-type="fig"}. Countries from which no publications on ME/CFS biomarker could be retrieved are shown in light green/grey, and European countries not participating in the EUROMENE are shown in white. The references listed per countries are shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Biomarker studies were categorized as metabolic, immunological, neurological or infection-associated. The data was visualized as total numbers of studies (size of cake) per category (piece of cake) from each country, and the numbers of active biomarker research groups is indicated in the countries. EUROMENE countries are indicated by *grey* (*dark grey* countries with published studies, *light grey* those without studies) and non-EUROMENE by *white* Table 1ME/CFS biomarker studies in Europe 2012--2016CountryCategoryStudy referencesBelgiumMetabolic\[[@CR27]\]Immunologic\[[@CR3]\]FranceMetabolic\[[@CR28], [@CR29]\]GermanyMetabolic\[[@CR30]\]Immunologic\[[@CR4]--[@CR7]\]Neurologic\[[@CR23]\]IrelandImmunologic\[[@CR8]\]ItalyMetabolic\[[@CR31]--[@CR34]\]Infection\[[@CR18], [@CR19]\]LatviaInfection\[[@CR20], [@CR21]\]NetherlandsMetabolic\[[@CR35], [@CR36]\]NorwayMetabolic\[[@CR37]\]Immunologic\[[@CR9], [@CR10]\]Neurologic\[[@CR24], [@CR25]\]Poland\*Immunologic\[[@CR11]\]SerbiaMetabolic\[[@CR38]\]SpainMetabolic\[[@CR39]\]Immunologic\[[@CR12]\]Infection\[[@CR22]\]SwedenImmunologic\[[@CR13]\]UKMetabolic\[[@CR40], [@CR41]\]Immunologic\[[@CR14]--[@CR17]\]Neurologic\[[@CR26]\]\* Non-EUROMENE country

Studies on immune markers (n = 15) in ME/CFS explored immunoglobulins, autoantibodies, cytokines, and immune cell phenotype and function (summarized in Table [2](#Tab2){ref-type="table"}) \[[@CR3]--[@CR17]\]. Four of 5 of the studies on ME/CFS-associated infection markers were focused on XMRV and confirmed the absence of this virus in European ME/CFS cohorts \[[@CR18]--[@CR22]\]. Neurological biomarker studies (n = 4) focused on neurotransmitter regulation, but excluded imaging and functional studies \[[@CR23]--[@CR26]\]. The papers which could be retrieved for potential metabolic markers (n = 15) studied mitochondrial dysfunction, oxidative stress, cortisol regulation, and more comprehensive metabolic pathways \[[@CR27]--[@CR41]\].Table 2Immune marker studiesMarker^(Ref)^Design of studyME/CFS pat. n/diagnostic criteriaControls n/age- and sex-matchedSub group analysisValidation cohortResults in ME/CFS compared to healthy controlsImmunoglobulins (Ig), MBL \[[@CR4]\]Confirmatory300/CCCReference rangeYes16825% diminished Ig\
25% elevated Ig\
15% MBL diminishedB cells \[[@CR4]\]65/CCC20/no20B cell subsets not alteredIgG3 IgE COMT \[[@CR5]\]Exploratory76/CCC74/noYesNoCOMT rs4680 is associated with IgG3 and IgE levelsEBV-specific IgG\
EBV-B and T cells \[[@CR7]\]Confirmatory\
Exploratory63/CDC\
1757/no\
12/noYes387\
NoMore EBNA-IgG neg.\
More VCA-IgM pos\
EBV B-/T cells lowerHSP60 auto-antibodies \[[@CR13]\]Exploratory69/CCC76/noYes61Few IgG epitopes specific for ME/CFSNeurotransmitter-receptor auto-antibodies \[[@CR6]\]Exploratory/confirmatory268/CCC108/yesYesNoElevated β2 adrenergic, M3/4 cholinergic receptor antibodies in a subset of ME/CFSCytokines \[[@CR10]\]Exploratory120/CDC68/yesYesNoMultiple cytokines no differencesCytokines \[[@CR8]\]Exploratory48/CDC35/noNoNoElevated CRP, TNF-alpha and IL-6 levelsCytokines \[[@CR15]\]Review38 papersTGF-β levels elevated in 5 of 8 studies (63%)Cytokines \[[@CR3]\]Exploratory16/CDC14/yesNoNoIncrease of IL-1b, IL-8, IL-10 and TNF-alpha levelsBAFF, APRIL \[[@CR9]\]Exploratory70/CCC & CDC56/noYesNoElevated BAFF baseline\
APRIL not alteredT cells \[[@CR11]\]Exploratory139/CDC40/noYesNoIncreased CD38 expression on CD8^+^ T cellsNK, T and B cells \[[@CR12]\]Exploratory22/CDC30/noNoNoTreg higher, Tem lower, NK cell CD69, NKp46 higher, CD25 lower, B cell subsets not alteredB cells \[[@CR16]\]Exploratory38/CCC & CDC32/yesNoNoIncreased CD24 expression on total B cells\
Elevated number of CD21+ CD38− B cellsB cells \[[@CR14]\]Exploratory33/CCC & CDC24/yesNoNoIncreased number of naïve and transitional B cellsmiRNA in immune cell subsets \[[@CR17]\]Exploratory35/CCC & CDC50/noNoNo34 miRNAs upregulated in NK, B cells and monocytesDiagnostic criteria: *CDC* the Centers of Disease Control or Fukuda Criteria \[[@CR49]\], *CCC* Canadian Consensus Criteria

Discussion {#Sec3}
==========

So far there is no single biomarker available for diagnostic use in ME/CFS. Most studies identified here were exploratory in design and lack sex and age-matched control groups or validation cohorts thus having a low evidence level as summarized for the immune marker studies in Table [2](#Tab2){ref-type="table"} \[[@CR42]\]. Some studies report inconsistent data, too. For example an expansion of transitional and naïve B cells and reduced plasmablast levels was reported in one study \[[@CR14]\], but could not be confirmed in two other studies \[[@CR4], [@CR12]\]. Immune cell phenotype and function analyses are, of course, hampered by variations in sampling and methodological differences between laboratories as most flow cytometric assays are not standardized. Further, immunological biomarkers reported mostly show alterations in subgroups only or with wide overlap to healthy control groups. Such heterogeneous results may be related to the fact that subgroups of ME/CFS patients exist with different immunological pathomechanisms. This concept is supported by the existence of clinical subgroups with heterogeneity in disease onset (infection- versus non-infection triggered), the variability of immune-associated symptoms, and the divergent response to B cell depletion therapy \[[@CR43]\]. Research activity in infection markers on ME/CFS across Europe is sparse; however, there is currently no evidence from the available literature that there is a specific serological signature aiding in diagnosis of ME/CFS.

Similar to immunological markers, there is no single neurological or metabolic marker with sufficient specificity and sensitivity as a tool in ME/CFS diagnosis yet. However, recent studies analyzing multiple metabolites could show specific alterations in the majority of ME/CFS patients \[[@CR37], [@CR44]--[@CR46]\] pointing to a probably common and specific metabolic profile. Further, metabolic studies consistently revealed different gender-related patterns \[[@CR37], [@CR44], [@CR46]\]. Thus, instead of searching single markers fitting for diagnosing all patients, multiplexed determinations of biomarkers analyzing pathways together with patient stratification, may be necessary to develop diagnostic assays with sufficient sensitivity and specificity \[[@CR47]\].

Conclusions {#Sec4}
===========

Heterogeneity of biomarker studies with different case definitions, low number of patients, lack of matched control groups, missing validation studies and potentially subgroup heterogeneity are possible reasons why no diagnostic biomarkers are available yet. Further, as result of the low amount of funding in CFS/ME research few and often small studies were performed so far. Therefore, strategies to improve the quality and to facilitate the comparability of biomarker studies are needed (summarized in Table [3](#Tab3){ref-type="table"}). This starts with well-defined patient cohorts using strict case definitions \[[@CR47]\], standardized and quantitative symptom assessment for subgroup analyses, well-defined age- and sex-matched controls, and large enough cohort size and a predefined hypothesis to power the statistical analysis. Detailed description of cohorts, assays performed and results achieved are important to facilitate confirmation studies. Reproducing results in cohorts from different countries, developing Standard Operating Procedures (SOPs) for assays, and multi-center studies are important steps for evaluating the suitability of biomarkers of interest as diagnostic markers. The building of translational networks of clinical and basic research groups like promoted in EUROMENE is an important first step to achieve such goals. Finally, to promote research it is crucial to increase funding for ME/CFS which is currently still far below the budget funds for most other serious diseases in both the EU and the US funding agencies, such as the National Institutes of Health (NIH) \[[@CR48]\].Table 3Strategies for development of diagnostic biomarkers in ME/CFS1. Standardization of sample collection and assay procedures2. Use of an uniform clinical case definition3. Use of questionnaires to assess symptoms and severity to define subgroups4. Stratification of patients according to sex, disease onset, and disease duration5. Include sex- and age-matched control groups6. Sufficient sample size and predefined hypotheses (statistical power)7. Confirmation of results in validation and multi-center cohort studies8. Study combinations of biomarkers, perform pathway analysis or functional studies
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:   Fukuda Criteria (Centers for Disease Control and Prevention)

CFS

:   chronic fatigue syndrome
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:   catechol-*O*-methyltransferase

COST

:   Cooperation in Science and Technology
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:   C-reactive protein
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:   Epstein--Barr virus

EU

:   European Union
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:   European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
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:   mannose binding lectin

ME

:   myalgic encephalomyelitis

MeSH

:   medical subject headings

NIH

:   National Institutes of Health

NK

:   natural killer cells

RNA

:   ribonucleic acid

SOP

:   standard operating procedure

TGF

:   transforming growth factor
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:   tumor necrosis factor

US

:   United States of America
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:   viral capside antigen
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:   xenotropic murine leukemia virus-related virus
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